Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,778 total articles

Westport to Showcase High‑Pressure CNG Fuel System for North American Heavy‑Duty Fleets at ACT Expo 2026

Westport to Showcase High‑Pressure CNG Fuel System for North American Heavy‑Duty Fleets at ACT Expo 2026

Westport announced the first North American demonstration of its next-generation high-pressure (~700 bar) compressed natural gas (CNG) fuel storage system combined with Cespira's on-engine HPDI fuel system on a Volvo VNL 300 heavy-duty truck at ACT Expo 2026. The system delivers diesel-like performance and efficiency with significantly lower emissi…

BOS to Release First Quarter 2026 Results on May 28, 2026

BOS to Release First Quarter 2026 Results on May 28, 2026

BOS Better Online Solutions Ltd., an integrator of advanced supply chain technologies serving aerospace, defense, industrial, and retail sectors, will release its financial results for the first quarter of 2026 on May 28, 2026. The company will host a video conference call to discuss the results and answer investor questions. BOS operates three div…

Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology

Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology

Glucotrack, Inc. announced the publication of a peer-reviewed study in The Journal of Diabetes Research that demonstrates the long-term accuracy and stability of its fully implantable continuous blood glucose monitoring (CBGM) system. The preclinical ovine model study shows excellent accuracy over 240 days and no device-related adverse safety event…

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR

Fate Therapeutics announced clinical safety, efficacy, and translational data for its off-the-shelf CAR T-cell product candidate, FT819, in treating systemic lupus erythematosus (SLE). The Phase 1 study data demonstrated clinically meaningful and durable improvements in disease activity and patient-reported outcomes following a single dose combined…

Broadcom Accelerates Multi-Gig Broadband with Optimized 10G PON and Wi-Fi 8 Solutions for Mass Market

Broadcom Accelerates Multi-Gig Broadband with Optimized 10G PON and Wi-Fi 8 Solutions for Mass Market

Broadcom announced its latest Wi-Fi 8 dual-band radios and an optimized 10G PON gateway SoC designed to accelerate mass market broadband upgrades. These new products deliver enhanced performance, lower power consumption, and reduced costs, enabling service providers to offer more reliable, high-speed fiber-based connectivity in highly competitive m…

Arteris Wins Stevie Award for Technology Innovation of the Year

Arteris Wins Stevie Award for Technology Innovation of the Year

Arteris, Inc., a Nasdaq-listed semiconductor technology company, announced its Cycuity Radix technology has won a Bronze Stevie Award for Technology Innovation of the Year in the Software category. The innovation focuses on enhancing semiconductor cybersecurity assurance, critical for AI infrastructure across sectors such as data centers, automotiv…

AVITA Medical Names Cary Vance as Chief Executive Officer

AVITA Medical Names Cary Vance as Chief Executive Officer

AVITA Medical has appointed Cary Vance as its permanent President and CEO following his interim tenure, alongside the appointment of Jan Stern Reed as Chair of the Board. The leadership changes come after a thorough search and reflect confidence in Vance's ability to stabilize and grow the company amid strong clinician feedback on their wound care …

Primech Holdings Awarded Two Multi-Year Industrial Cleaning Contracts in Singapore Totaling Approximately US$3.45 Million

Primech Holdings Awarded Two Multi-Year Industrial Cleaning Contracts in Singapore Totaling Approximately US$3.45 Million

Primech Holdings Limited, a Nasdaq-listed Singapore-based integrated facility services provider, announced that its subsidiaries have won two separate three-year industrial cleaning contracts valued at approximately US$3.45 million. These contracts provide recurring revenue streams and align with Primech's strategic focus on industrial facility ser…

Versus Systems (NASDAQ: VS) Signs Additional Agreement with Texas Rangers Following Renewal of Partnership Through 2026 Major League Baseball Season

Versus Systems (NASDAQ: VS) Signs Additional Agreement with Texas Rangers Following Renewal of Partnership Through 2026 Major League Baseball Season

Versus Systems Inc. has renewed and expanded its partnership with the Texas Rangers through the 2026 MLB season, deploying an upgraded Filter Fan Cam platform. This technology enhances fan experience by allowing attendees to appear on stadium video boards with branded digital filters and real-time AR visual effects. The upgrades include improved fa…

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

Can-Fite BioPharma reported positive results from its Phase 2a trial of Namodenoson in advanced pancreatic cancer patients. The study showed preliminary evidence of clinical activity with stable disease in over 30% of evaluable patients, including prolonged treatment of one patient beyond 16 months. Namodenoson demonstrated a favorable safety profi…

TOMI Environmental Solutions Signs Letter of Intent for a Merger with Carbonium Core, Inc., a U.S.-Based Producer of Nuclear-Grade Graphite for Advanced Reactors and Infrastructure Demands of AI Data Centers

TOMI Environmental Solutions Signs Letter of Intent for a Merger with Carbonium Core, Inc., a U.S.-Based Producer of Nuclear-Grade Graphite for Advanced Reactors and Infrastructure Demands of AI Data Centers

TOMI Environmental Solutions, listed on Nasdaq as TOMZ, has signed a non-binding letter of intent to merge with U.S.-based Carbonium Core, a producer of nuclear-grade graphite for advanced reactor technologies and AI data center infrastructure. This merger aims to diversify TOMI's business by adding a vertically integrated, domestically controlled …

FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

FibroBiologics, a clinical-stage biotech company specializing in fibroblast-based therapies, announced it will present preclinical data from its CYPS317 program targeting psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting. The presentation showcases the company’s progress in developing novel treatments for chronic diseases u…

Critical Metals Corp. Closes Acquisition of Final 50.5% Interest in Tanbreez, Bringing Current Ownership to 92.5%

Critical Metals Corp. Closes Acquisition of Final 50.5% Interest in Tanbreez, Bringing Current Ownership to 92.5%

Critical Metals Corp. has closed the acquisition of an additional 50.5% interest in the Tanbreez Mining Greenland project, bringing its ownership to 92.5%. The company issued 14.5 million shares for the transaction and announced a non-binding letter of intent to acquire the remaining 7.5% from European Lithium Ltd. Tanbreez is one of the world's la…

Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026

Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026

Quoin Pharmaceuticals Ltd., a NASDAQ-listed specialty pharmaceutical company focusing on rare and orphan diseases, announced it will release its first quarter 2026 financial results and provide a corporate update on May 7, 2026, including operational and financial highlights as well as recent achievements related to its late clinical-stage pipeline…

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange

Enlivex Ltd., a Nasdaq-listed longevity therapeutics company, announced that its digital treasury asset, the RAIN token, has been listed on HTX, a leading global cryptocurrency exchange. This listing expands the global accessibility and liquidity of the RAIN token, which underpins Enlivex's prediction markets treasury strategy. The company holds ap…

Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)

Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)

Microbot Medical Inc., a US-listed medical device company specializing in robotic endovascular procedures, announces the appointment of Alon Tamir as VP of Sales for Europe, Middle East, and Asia (EMEA). This strategic hire supports the company's planned expansion beyond the US following FDA clearance and a full market release of its LIBERTY Endova…

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

Pliant Therapeutics announced the dosing of the first patient in the FORTIFY Phase 1b clinical trial examining PLN-101095 combined with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. The trial targets three patient cohorts: non-small cell lung cancer (NSCLC), clear cell renal cell ca…

Alliance Entertainment to Host Third Quarter Fiscal Year 2026 Results Conference Call on May 14 at 4:30 p.m. Eastern Time

Alliance Entertainment to Host Third Quarter Fiscal Year 2026 Results Conference Call on May 14 at 4:30 p.m. Eastern Time

Alliance Entertainment Holding Corporation, a leading distributor and fulfillment partner in the entertainment and pop culture collectibles sector, has scheduled its third quarter fiscal year 2026 results conference call for May 14, 2026. Executives will discuss the company's financial performance ended March 31, 2026, followed by a Q&A session. Th…

InterDigital Announces Financial Results for First Quarter 2026

InterDigital Announces Financial Results for First Quarter 2026

InterDigital announced its financial results for Q1 2026, highlighting six new licensing agreements including a renewal with Xiaomi and a new license with LG Electronics. The company achieved record smartphone annualized recurring revenue (ARR) of $491.8 million, a 18% increase year-over-year, and surpassed the top end of its guidance for revenue, …